Aerovate Therapeutics (AVTE) News Today → is this a buy and hold stock? (From Tips4Traders) (Ad) Free AVTE Stock Alerts $20.45 +1.17 (+6.07%) (As of 01:01 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:42 AM | marketbeat.comResearch Analysts Set Expectations for Aerovate Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:AVTE)Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Equities research analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Aerovate Therapeutics in a report issued on Tuesday, May 14th. Wedbush analyst L. Chico expects that the company will earn ($0.68) per shMay 15 at 6:22 AM | americanbankingnews.comAerovate Therapeutics (NASDAQ:AVTE) Receives "Outperform" Rating from WedbushMay 14 at 3:40 PM | msn.comAerovate Therapeutics reports Q1 GAAP EPS of -$0.83May 13 at 11:05 PM | investorplace.comAVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024May 13 at 4:30 PM | globenewswire.comAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsMay 12 at 8:26 AM | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Increase in Short InterestAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 1,880,000 shares, a growth of 50.4% from the April 15th total of 1,250,000 shares. Currently, 10.4% of the shares of the company are short sold. Based on an average daily volume of 143,800 shares, the short-interest ratio is presently 13.1 days.May 12 at 6:03 AM | americanbankingnews.comAerovate Therapeutics (NASDAQ:AVTE) Shares Down 6.1% May 10, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 6.1%Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 6.1%May 5, 2024 | americanbankingnews.comMarinus Verwijs Sells 1,981 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockMay 5, 2024 | americanbankingnews.comTimothy P. Noyes Sells 11,357 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockMay 4, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Marinus Verwijs Sells 1,981 SharesApril 29, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 4.6%Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 4.6%April 24, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Sees Large Volume IncreaseAerovate Therapeutics (NASDAQ:AVTE) Sees Unusually-High Trading VolumeApril 21, 2024 | insidertrades.comBenjamin T. Dake Sells 6,853 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockApril 20, 2024 | investing.comAerovate Therapeutics exec sells shares worth over $153,000April 20, 2024 | investing.comAerovate Therapeutics CEO sells over $246k in company stockApril 19, 2024 | marketbeat.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 6,853 Shares of StockAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) insider Benjamin T. Dake sold 6,853 shares of the firm's stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $22.37, for a total value of $153,301.61. Following the completion of the sale, the insider now directly owns 1,291 shares of the company's stock, valued at approximately $28,879.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.April 19, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Sells $247,000.00 in StockApril 18, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 3.8%Aerovate Therapeutics (NASDAQ:AVTE) Shares Down 3.8%April 15, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 9.9% in MarchAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 993,100 shares, a growth of 9.9% from the March 15th total of 903,700 shares. Based on an average trading volume of 130,200 shares, the days-to-cover ratio is presently 7.6 days. Approximately 5.8% of the company's stock are short sold.April 13, 2024 | insidertrades.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 7,500 Shares of StockApril 12, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Down 5.4% After Insider SellingAerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 5.4% After Insider SellingApril 12, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Director Sells $334,478.30 in StockApril 11, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Director David S. Grayzel Sells 11,882 SharesAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) Director David S. Grayzel sold 11,882 shares of the firm's stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $28.15, for a total transaction of $334,478.30. Following the completion of the sale, the director now directly owns 14,502 shares of the company's stock, valued at approximately $408,231.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.April 9, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Up 7.3%Aerovate Therapeutics (NASDAQ:AVTE) Trading Up 7.3%April 4, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 3,325 SharesApril 4, 2024 | finance.yahoo.comAerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 SharesApril 3, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Down 3.9%Aerovate Therapeutics (NASDAQ:AVTE) Shares Down 3.9%April 2, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Shares Gap Down to $30.75Aerovate Therapeutics (NASDAQ:AVTE) Shares Gap Down to $30.75April 2, 2024 | markets.businessinsider.comAerovate Therapeutics: Poised for Market Capitalization Growth on IMPAHCT Trial SuccessApril 1, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Stock Rating Reaffirmed by Wells Fargo & CompanyWells Fargo & Company reiterated an "overweight" rating and issued a $35.00 target price on shares of Aerovate Therapeutics in a report on Monday.April 1, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Reaches New 1-Year High at $30.73Aerovate Therapeutics (NASDAQ:AVTE) Reaches New 1-Year High at $30.73April 1, 2024 | msn.comAerovate Therapeutics (NASDAQ:AVTE) on the Verge of Substantial GrowthMarch 31, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Large Decline in Short InterestAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 903,700 shares, a decrease of 10.5% from the February 29th total of 1,010,000 shares. Approximately 5.3% of the shares of the company are sold short. Based on an average daily volume of 102,500 shares, the short-interest ratio is currently 8.8 days.March 29, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 11,068 SharesMarch 28, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 3,432 SharesMarch 27, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Shares Gap Up to $25.65Aerovate Therapeutics (NASDAQ:AVTE) Shares Gap Up to $25.65March 27, 2024 | globenewswire.comAerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceMarch 27, 2024 | finance.yahoo.comAerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023March 26, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Down 8.8%Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 8.8%March 26, 2024 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 26, 2024 | marketbeat.comAerovate Therapeutics (AVTE) to Release Earnings on WednesdayAerovate Therapeutics (NASDAQ:AVTE) will be releasing earnings on Wednesday, March 27, Yahoo Finance reports.March 26, 2024 | markets.businessinsider.comAerovate Therapeutics: A Strong Buy Ahead of Key Clinical Data ReleaseMarch 25, 2024 | benzinga.comRecap: Aerovate Therapeutics Q4 EarningsMarch 25, 2024 | investorplace.comAVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023March 25, 2024 | markets.businessinsider.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 25, 2024 | globenewswire.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 25, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Reaches New 12-Month High at $28.39Aerovate Therapeutics (NASDAQ:AVTE) Hits New 1-Year High at $28.39March 25, 2024 | marketbeat.comAerovate Therapeutics' (AVTE) "Buy" Rating Reiterated at Jefferies Financial GroupJefferies Financial Group reaffirmed a "buy" rating and issued a $65.00 price objective (up from $21.00) on shares of Aerovate Therapeutics in a report on Monday.March 24, 2024 | morningstar.comAerovate Therapeutics Inc AVTE Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (Ad)Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it. This means you must act NOW before it's too late. AVTE Media Mentions By Week AVTE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVTE News Sentiment▼0.170.56▲Average Medical News Sentiment AVTE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVTE Articles This Week▼142▲AVTE Articles Average Week Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ArriVent BioPharma News Today IGM Biosciences News Today Avid Bioservices News Today Applied Therapeutics News Today Astria Therapeutics News Today Phathom Pharmaceuticals News Today Arbutus Biopharma News Today COMPASS Pathways News Today Calliditas Therapeutics AB (publ) News Today Larimar Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVTE) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trendsis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
